The global hepatitis e vaccines market was valued at USD 45.6 million in 2025. The market is projected to grow from USD 55.2 million in 2026 to USD 247.5 million by 2034, exhibiting a compound annual growth rate of 20.62% during the forecast period. Contrive Datum Insights presents this information in its report titled "Hepatitis E Vaccines Market Size, Share & Industry Analysis, By Vaccine type / platform technology (Recombinant Protein / Virus-Like Particle (VLP) Vaccines, DNA-Based Vaccine Candidates, mRNA-Based Vaccine Candidates, Live-Attenuated Vaccine Candidates, Inactivated Whole-Virus Vaccine Candidates), Development & regulatory stage (Licensed / Commercially Marketed, Phase III Clinical Trials, Phase II Clinical Trials, Phase I Clinical Trials, Preclinical Research Stage), Genotype coverage / antigen target (Genotype 1-Derived Antigen Candidates, Genotype 4-Relevant Candidates, Genotype 3-Relevant Candidates, Genotype 2-Relevant Candidates, Pan-Genotype (Cross-Protective) Candidates), Dosing regimen (Three-Dose Regimen (0, 1, 6 Months), Two-Dose Regimen (0, 1 Month), Single-Dose Candidates (Investigational)), Target population / risk group (Women of Reproductive Age, Including Pregnant Women, General Adult Population in Endemic Areas, Children and Adolescents, Immunocompromised and Chronic Liver Disease Patients, Travelers to Endemic Regions, Military and Occupational-Risk Personnel), Application / use setting (Routine National Immunization Programs, Outbreak and Emergency Response Campaigns, Travel Medicine / Pre-Travel Vaccination, Occupational and Institutional Vaccination, Clinical Research and Trial Use), Distribution / procurement channel (Government and National Immunization Programs, International and Multilateral Procurement, Private Hospitals and Clinics, Travel Medicine and Specialty Vaccination Clinics, Humanitarian and NGO-Led Outbreak Response Procurement), Adjuvant system (Aluminum Hydroxide (Alum)-Adjuvanted, Non-Adjuvanted / Antigen-Only Formulations, Novel / Next-Generation Adjuvant Systems (Investigational)), End user (Hospitals and Clinics, Government and Public Health Immunization Bodies, Travel Medicine and Occupational Health Clinics, Humanitarian and Outbreak-Response Organizations, Academic and Research Institutes), Route of administration (Intramuscular Injection (Standard), Investigational Needle-Free / Alternative Delivery Candidates), and Regional Forecast, 2026-2034".
Hepatitis E vaccines are prophylactic biologics developed to prevent infection with the hepatitis E virus, a pathogen transmitted primarily through contaminated water that causes acute liver disease and carries an elevated mortality risk during pregnancy. The category spans a single vaccine already licensed and administered in one national market alongside a pipeline of recombinant, DNA-based, mRNA-based, live-attenuated and inactivated candidates still in clinical development. Buyers include national immunization programs in endemic countries, international procurement bodies coordinating outbreak-response stockpiles, private hospitals and travel medicine clinics, and research institutes running clinical trials.
Licensure and national program adoption spreading beyond the first market
Licensure and national program adoption spreading beyond the first market is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 20.62% a year, the vaccine type / platform technology lines exposed to it move fastest: mRNA-Based Vaccine Candidates compounds at 44.57%, taking its share of revenue from 2.5% to 14.5% and its value from USD 1.14 million to USD 35.89 million.
On the upside, the study's bull case assumes bull case assumes at least one additional country completes licensure and lists the vaccine in its routine national immunization program within the forecast window, pulling program-channel volume forward faster than the base case, which would take 2034 revenue to USD 267.3 million against the USD 247.5 million base case.
On the downside, bear case assumes multilateral stockpile funding is renewed on a reduced scale and no additional country reaches routine program listing within the forecast window, holding growth to the outbreak-response channel alone, which would hold 2034 revenue to USD 227.7 million. Recombinant Protein / Virus-Like Particle (VLP) Vaccines, which carries 90.5% of 2025 revenue, already grows at only 15.23% against the market's 20.62%, so the largest part of the base is also its slowest.
The Competitive Split Runs by Vaccine type / platform technology
Suppliers here are separated by vaccine type / platform technology, not by geography. The incumbent position is Recombinant Protein / Virus-Like Particle (VLP) Vaccines: 90.5% of 2025 revenue, USD 41.27 million, and still 61% in 2034. The contested position is mRNA-Based Vaccine Candidates at 44.57% growth. Few suppliers hold both, which is why a market of USD 45.6 million supports as many participants as it does.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Vaccine type / platform technology | Recombinant Protein / Virus-Like Particle (VLP) Vaccines | 90.5% · USD 41.27 million | — |
| Development & regulatory stage | Licensed / Commercially Marketed | 91% · USD 41.5 million | Phase III Clinical Trials 36.37% |
| Genotype coverage / antigen target | Genotype 1-Derived Antigen Candidates | 42% · USD 19.15 million | Pan-Genotype (Cross-Protective) Candidates 37.33% |
| Dosing regimen | Three-Dose Regimen (0, 1, 6 Months) | 82% · USD 37.39 million | Single-Dose Candidates (Investigational) 39.14% |
| Target population / risk group | Women of Reproductive Age, Including Pregnant Women | 32% · USD 14.59 million | Immunocompromised and Chronic Liver Disease Patients 23.71% |
| Application / use setting | Routine National Immunization Programs | 38% · USD 17.33 million | Travel Medicine / Pre-Travel Vaccination 22.77% |
| Distribution / procurement channel | Government and National Immunization Programs | 40% · USD 18.24 million | Private Hospitals and Clinics 22.49% |
| Adjuvant system | Aluminum Hydroxide (Alum)-Adjuvanted | 70% · USD 31.92 million | Novel / Next-Generation Adjuvant Systems (Investigational) 35.02% |
| End user | Hospitals and Clinics | 34% · USD 15.5 million | Travel Medicine and Occupational Health Clinics 22.49% |
| Route of administration | Intramuscular Injection (Standard) | 96% · USD 43.78 million | Investigational Needle-Free / Alternative Delivery Candidates 36.37% |
- Regionally, the lead sits with Asia Pacific: 78% of 2025 global revenue, USD 35.57 million rising to USD 153.45 million in 2034.
- Middle East and Africa takes a rising share of global revenue over the forecast period, from 12% in 2025 to 24% in 2034, with revenue growing from USD 5.47 million to USD 59.4 million.
- Latin America remains the smallest region throughout, at 2% of 2025 revenue and 3% by 2034.
- The fastest vaccine type / platform technology line is mRNA-Based Vaccine Candidates, forecast to compound at 44.57% through the period.
- China is the largest single country market at USD 24.9 million in 2025, 54.6% of global revenue.
The study covers ten axes, by vaccine type / platform technology, and by development & regulatory stage, genotype coverage / antigen target, dosing regimen, target population / risk group, application / use setting, distribution / procurement channel, adjuvant system, end user and route of administration, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 227.7 million and USD 267.3 million by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.